IntoCell
Daily close in US$ at the latest USD/KRW close. Source: KRX via FinanceDataReader.
IntoCell develops the chemical components, linkers and payloads, that sit at the heart of antibody-drug conjugates (ADCs), a class of targeted cancer medicines that attach a potent cell-killing drug to an antibody so it can seek out and destroy cancer cells while sparing healthy tissue.
Its platform technologies are designed to be licensed or supplied to pharmaceutical and biotech companies developing ADC drug candidates. The company's core focus is its proprietary OHPAS linker platform, which it says can work with a broader range of drug molecules than the main competing linker technology. IntoCell is listed on KOSDAQ, South Korea's tech-oriented small-cap exchange.
Summary is AI-generated and may contain errors · figures from DART filings
IntoCell in five facts
What does IntoCell do?
IntoCell develops the chemical components, linkers and payloads, that sit at the heart of antibody-drug conjugates (ADCs), a class of targeted cancer medicines that attach a potent cell-killing drug to an antibody so it can seek out and destroy cancer cells while sparing healthy tissue.
Where is IntoCell listed and in which sector?
IntoCell (Korean name: 인투셀) trades under KRX code 287840 on KOSDAQ, the Korea Exchange's board for smaller and growth companies. It is classified in the Industrials sector, Commercial Services.
How large is IntoCell?
Its market capitalisation was US$188.3M on 2026-10-21, which puts it in this site's small-cap group. US$ amounts are converted from won at 1 USD ≈ ₩1,325 (2026-10-21).
What were IntoCell's latest annual revenue and operating profit?
For fiscal year 2025, IntoCell reported revenue of US$1.7M, an operating loss of US$7.8M and a net loss of US$8M, per its annual report on DART (data retrieved from DART on 2026-06-03). Revenue was down 20.9% on the previous year.
Where does this data come from?
Financial statements and filings come from DART, Korea's official corporate-filing system. Share prices, market capitalisation and trading status come from KRX. Company summaries are AI-generated from the filings and may contain errors; financial figures are mapped directly from DART.
Data sources and last updated
- Filings and financial statements
- DART (dart.fss.or.kr), Korea's official corporate-filing system
- Prices, market cap, trading status
- KRX (Korea Exchange), via FinanceDataReader
- Latest annual financials
- Fiscal year 2025, data retrieved from DART on 2026-06-03
- Share price and market cap
- Close of 2026-10-21
- Currency
- US$, converted from won at 1 USD ≈ ₩1,325 (2026-10-21 close)
- Company data updated
- 2026-10-21
- Company summary
- AI-generated from filings; may contain errors. Information only, not investment advice.